Cardiovascular Disease

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

The first study of its kind found that intensive blood pressure control may be most beneficial in older adults with life expectancy greater than 3 years vs less than 1 year.

One-half of more than 600 000 patients with ASCVD were not prescribed statins at all and only 22.5% were taking a high intensity statin, according to a recent study.

Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.

In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.

The patient is a young man who presents after resolution of several hours of chest pain. He is recovering from a lower GI illness and still taking Cipro. What's your Dx?

New study presented at Heart Rhythm 2022 showed applying AI to an Apple Watch ECG can effectively identify LV dysfunction in a nonclinical setting.

Seven risk factors accounted for 85% of the risk of first acute myocardial infarction in young adults in a new study.

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

Black patients hospitalized with atrial fibrillation were 25% less likely to receive oral anticoagulants upon discharge according to a large national registry study.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.

USPSTF states low-dose aspirin should be considered for CVD prevention on a case-by-case basis in adults aged 40-59 yrs with a 10% or greater 10-year CVD risk.

Dylan Steen, MD talks about several SuperWIN results that caught him happily by surprise and suggest plenty of room for follow-up research.

NAFLD is a key risk factor for ASCVD and widely underdiagnosed. This Guideline Topline summarizes new AHA warnings, guidance.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

Patients who received a low-dose 3-drug combination pill achieved time at BP target of 64% vs the usual care group result of 43% in a post-hoc analysis of TRIUMPH.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

Coprincipal investigator Steen highlights the first-of-its kind study and the findings—local in-store dietitian counseling/feedback, nutrition education, and online shopping savvy improve food choices, health metrics.

Obesity significantly increased the risk of heart failure among women who experienced menopause at age ≥55 years in a new study.

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

The FDA clearance for the FitBit algorithm will provide another widely tested tool for patient and clinicians to help identify arrhythmias earlier and avoid severe cardiocerebrovascular events.

ACC 2022: Use of antihypertensive therapy in pregnant women was associated with better pregnancy outcomes, such as preeclampsia and fetal or neonatal death.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

ACC 2022. An EHR alert tailored to prompt clinicians to check guideline-directed medical therapy for individual HF patients was integrated carefully into clinical workflow.

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.

ACC 2022. Findings suggest that more attention to monitoring cognitive functioning after a myocardial infarction is needed.

The higher dose of the GLP-1 analogue allows more flexibility for patients with T2D needing to intensify treatment, says manufacturer Novo Nordisk.